Internal Medicine, Pulmonary Disease · Springfield, MA
NPI
1083604870
Since 2005
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
2150 Main St
Springfield, MA, 01104
Phone (413) 739-5676
Groups this clinician bills Medicare through
Medicare paid, 2024
$147K
2,583 services
Medicare patients, 2024
1,020
Average age 73
Drug cost, 2024
$4.1M
8,851 prescriptions
Company payments, 2025
$1,197
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Chih M Chen was code 99214 (office e&m - established), 748 times for 467 patients. In total Chih M Chen billed 2,583 services in 27 codes, and Medicare paid $147K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-02-24.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 748 | 467 | $92.00 | $69K |
| 94060 Pulmonary Function Testing | Office | 265 | 256 | $29.46 | $7,807 |
| 94729 Pulmonary Function Testing | Office | 254 | 247 | $44.26 | $11K |
| 94727 Pulmonary Function Testing | Office | 254 | 247 | $33.20 | $8,434 |
| 99213 Office E&M - Established | Office | 232 | 213 | $65.72 | $15K |
| 94618 Pulmonary Function Testing | Office | 119 | 115 | $25.72 | $3,061 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 104 | 103 | $12.80 | $1,331 |
| 94060 Pulmonary Function Testing | Facility | 98 | 98 | $7.63 | $748 |
| 94727 Pulmonary Function Testing | Facility | 97 | 97 | $8.90 | $864 |
| 94729 Pulmonary Function Testing | Facility | 95 | 95 | $6.60 | $627 |
| 99232 Hospital E&M - Subsequent | Facility | 69 | 32 | $61.93 | $4,273 |
| 99204 Office E&M - New | Office | 51 | 51 | $123.39 | $6,293 |
| 99223 Hospital E&M - Initial | Facility | 49 | 45 | $136.03 | $6,666 |
| 99406 Behavioral Health Services | Office | 44 | 44 | $14.65 | $645 |
| 99215 Office E&M - Established | Office | 41 | 37 | $133.68 | $5,481 |
By year: 2022 $138K for 2,397 services; 2023 $144K for 2,576 services; 2024 $147K for 2,583 services.
Medicare prescription drug claims, 2024
In 2024, the drug Chih M Chen prescribed most often to Medicare patients was Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter), with 1,538 prescriptions and refills. In total Chih M Chen wrote 8,851 Medicare prescriptions that cost $4.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 1,538 | 1,795 | 260 | $1.1M |
| Albuterol Sulfate Hfa Albuterol Sulfate | 1,377 | 1,480 | 393 | $40K |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | 703 | 842 | 132 | $375K |
| Prednisone Generic | 536 | 576 | 161 | $2,365 |
| Wixela Inhub Fluticasone Propion/Salmeterol | 510 | 612 | 104 | $60K |
| Breo Ellipta Fluticasone/Vilanterol | 468 | 525 | 81 | $208K |
| Montelukast Sodium Generic | 414 | 883 | 102 | $5,648 |
| Ventolin Hfa Albuterol Sulfate | 386 | 408 | 103 | $24K |
| Incruse Ellipta Umeclidinium Bromide | 379 | 440 | 63 | $149K |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 260 | 340 | 53 | $37K |
| Azithromycin Generic | 218 | 330 | 72 | $2,183 |
| Advair Hfa Fluticasone Propion/Salmeterol | 208 | 246 | 43 | $85K |
| Combivent Respimat Ipratropium/Albuterol Sulfate | 202 | 242 | 45 | $120K |
| Spiriva Respimat Tiotropium Bromide | 166 | 224 | 38 | $102K |
| Arnuity Ellipta Fluticasone Furoate | 150 | 170 | 37 | $36K |
Brand drugs: 6,129 claims; generic drugs: - claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Chih M Chen $1,197 ($1,197 in general payments such as food, travel and fees) from 10 companies. The largest payer was Boehringer Ingelheim Pharmaceuticals, Inc. with $263.
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 9 | $263 |
| GlaxoSmithKline, LLC. GSK | 14 | $248 |
| Genzyme Corporation SNY | 3 | $225 |
| AstraZeneca Pharmaceuticals LP AZN | 7 | $167 |
| Grifols USA, LLC | 3 | $83.39 |
| Amgen Inc. AMGN | 3 | $60.64 |
| Janssen Biotech, Inc. JNJ | 1 | $44.03 |
| Verona Pharma, Inc. VRNA | 2 | $41.48 |
| Regeneron Healthcare Solutions, Inc. REGN | 2 | $38.24 |
| Pulmonx Corporation LUNG | 1 | $26.24 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.